Motor neurone disease is an enigmatic disorder characterized by progressive degeneration of anterior horn cells and motor nerves leading to skeletal muscle atrophy and premature death. Disturbances of carbohydrate metabolism, including glucose intolerance, are a well recognized feature of this disorder.' Plasma immunoreactive insulin concentrations, however, have been reported to be either normal,' decreased.s or elevated." To date, proinsulin-like molecules have not been examined.
In this study we measured the fasting concentrations of B cell products in a group of patients with motor neurone disease using immunoradiometric assays. These assays allow more accurate separation of insulin and proinsulin-like molecules than conventional radioimmunoassays." Using these assays, we have found elevated fasting plasma concentrations of proinsulin-like molecules in the neuromuscular wasting disorder myotonic dystrophy. 5 
PATIENTS AND METHODS

Patients
Eight patients with motor neurone disease, none with a history of diabetes in a first degree relative, were studied. With the exception of a single patient who was confined to a wheelchair all were ambulant. Eight healthy subjects with sedentary lifestyles served as normal controls. None was receiving medication known to interfere with carbohydrate metabolism or {1 cell function. Active hepatic and renal disease were excluded by clinical and biochemical tests.
Correspondence: Dr Malcolm Nattrass, The General Hospital, Steelhouse Lane, Birmingham B4 6NH, UK All subjects consumed ad libitum diets prior to study. Informed written consent was obtained and the study was approved by the Ethical Committee of the Central Birmingham Health Authority.
Protocol After a 10 h overnight fast, free-flowing venous blood was withdrawn from each subject and placed in a tube containing lithium heparin (LIP, Shipley, UK). The blood was promptly centrifuged at 4°C and plasma stored at -20°C pending assay. Glucose tolerance was assessed with a 75 g glucose challenge.P Assays Insulin, intact proinsulin, 32-33 split proinsulin and 65-66 split proinsulin were measured using two-site monoclonal antibody-based immunoradiometric assays (IRMAs) with between assay variation of 15070 or less and detection limits of O:8 to 2· 5 pmol/L. 4 Plasma C-peptide concentrations were measured with a kit (Novo Industries, Bagsvaerd, Denmark) using guinea pig anti-human C-peptide serum precipitated by 30% polyethylene glycol. Cross-reactivity was 80% with proinsulin. The lower limit of detection of the assay was 20 pmol/L with an intra-assay CV of 5' 4% at [mean (SD)] IDO (10) nmol/L and 4· 3% at 230 (10) pmol/L. Venous whole blood was measured using an automated fluorimetric hexokinase/glucose-6-phosphate dehydrogenase technique.
Statistical analysis
Differences between the groups were examined using Student's t test for unpaired data. Plasma {1 cell products were logarithmically transformed prior to analysis. Results are presented as mean (SEM). While fasting venous whole blood glucose concentration was not significantly different between the groups [4· 8 (0' 2) versus 5·2 (0' 2) mmol/L, P>O· I J, six of the motor neurone disease patients had impaired glucose tolerance." Glucose tolerance was normal in the remainder of subjects in each group.
Fasting plasma insulin concentration was not significantly different between the groups CONCLUSIONS While the fasting concentrations of B cell products were slightly higher in the patients with motor neurone disease compared with the healthy control subjects no statistically significant differences in insulin or proinsulin-like molecules (b) were observed between the groups. In contrast to our findings in myotonic dystrophy the results of this study indicate that fasting hyperproinsulinaemia is not a feature of glucose-intolerant patients with motor neurone disease.
(P>O'OI; Fig. I) . Similarly, no significant difference was observed in fasting C-peptide or proinsulin concentrations between the groups (P>O'I; Fig. I ). Only the difference in 32-33 split proinsulin approached statistical significance (P= 0'07; Fig. I ), the concentration of this molecule being higher in the subjects with motor neurone disease. Exclusion of the two motor neurone disease patients with normal glucose tolerance did not alter the results.
The results of this study contrast with our findings in patients with myotonic dystrophy in whom we demonstrated pronounced fasting hyperproinsulinaemia. S While inclusion of a larger number of patients may have increased the statistical power of the present study the biological significance of the minor difference observed in fasting concentrations of 32-33 split proinsulin between the groups would remain open to question . 
